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Abstract
Background: There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single drugs have failed
clinical trials suggesting a role for drug combinations. Drug combinations acting synergistically often provide the greatest
combination of potency and safety. The drugs examined (minocycline (MINO), N-acetylcysteine (NAC), simvastatin,
cyclosporine A, and progesterone) had FDA-approval for uses other than TBI and limited brain injury in experimental TBI
models.
Methodology/Principal Findings: Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI
model in adult rats. One week later, drugs were tested for efficacy and drug combinations tested for synergy on a hierarchy
of behavioral tests that included active place avoidance testing. As monotherapy, only MINO improved acquisition of the
massed version of active place avoidance that required memory lasting less than two hours. MINO-treated animals,
however, were impaired during the spaced version of the same avoidance task that required 24-hour memory retention. Co-
administration of NAC with MINO synergistically improved spaced learning. Examination of brain histology 2 weeks after
injury suggested that MINO plus NAC preserved white, but not grey matter, since lesion volume was unaffected, yet myelin
loss was attenuated. When dosed 3 hours before injury, MINO plus NAC as single drugs had no effect on interleukin-1
formation; together they synergistically lowered interleukin-1 levels. This effect on interleukin-1 was not observed when the
drugs were dosed one hour after injury.
Conclusions/Significance: These observations suggest a potentially valuable role for MINO plus NAC to treat TBI.
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Introduction
Despite its high prevalence in the population, only palliative
treatments are available for TBI [1,2]. A recent NIH workshop
on combination drug therapy for TBI concluded that past
failures in clinical trials resulted, in part, from preclinical testing
that selected drugs with insufficient potency [2]. Combination
therapy has become the standard of care for many common
diseases including cancer, hypertension, tuberculosis and AIDS
[3,4,5,6]. Combination therapies were developed to treat these
diseases since monotherapy was no longer effective. Combina-
tion therapy may also be advantageous for TBI even though
monotherapy has not shown to be effective. TBI damages the
brain in many ways; multiple drugs with disparate mechanisms
of action may better interfere with these injury mechanisms.
Greater potency can be achieved using synergistic drug
combinations, but drug pairs may have synergistic adverse
e f f e c t sa sw e l l[ 7 ] .A d v e r s ee ffects in drug combinations can
potentially be avoided by combining FDA-approved drugs with
known drug interactions.
Inadequate preclinical testing may have also contributed to the
failure of clinical trials [1,2]. Preclinical testing has evaluated lesion
volume; cell loss; blood-brain barrier permeability; intracranial
pressure; brain edema; and measures of apoptosis, inflammation,
or oxidative stress as markers of drug efficacy [1,2]. These markers
measure important components of brain injury, yet drugs that
improved these outcomes failed clinical trials [2].
A hierarchy of behavioral tasks has been developed that places a
high cognitive demand on rats [8]. This hierarchy may provide a
more stringent test for drug efficacy than previous behavioral or
histological tests [9]. The first two tasks of the behavioral hierarchy
were the open field and passive place avoidance [8]. These tests
examined basic motor, sensory and motivational parameters. Rats
receiving moderate or sham-CCI have been previously shown to
perform similarly on the open field and passive place avoidance
tests [8]. The equivalent performance sham- or moderate-CCI
injured rats in the open field and passive place avoidance suggests
intact innate behaviors, as well as similar levels of anxiety,
motivation, sensory and motor ability [8]. Active place avoidance,
the third and final task in the hierarchy tested whether rats with
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zone on a rotating arena. Optimal performance of active place
avoidance requires perceptual segregation since rats must attend to
distal, stationary visual cues to identify the location of the shock
zone while ignoring irrelevant proximal, rotating olfactory cues
that are not informative [10,11]. The active place avoidance task
places a high cognitive demand on rats that goes beyond memory,
although the task is also sensitive to short-term and long-term
memory impairments [11,12]. Injecting one hippocampus with the
sodium channel blocker tetrodotoxin completely impaired active
place avoidance learning [13]. The identical tetrodotoxin
treatment did not prevent rats from learning the location of the
escape platform in the Morris water maze, another test of spatial
memory and navigation [9]. Sham-injured rats optimally learned
the massed version of the active place avoidance task that consisted
of six 10-minute trials with a 10-minute intertrial interval [8]. In
contrast, moderate CCI produced large, long-lasting active place
avoidance deficits during massed training [8]. Cognitive deficits
were responsible for the impaired active place avoidance since
injured rats showed no motivational, behavioral, sensory or motor
deficits. This study used the active place avoidance task to examine
whether drugs can limit cognitive deficits produced by moderate
CCI. Rats receiving mild CCI or moderate CCI showed similar
performance on the first two tasks of the hierarchy. On the third
task, active place avoidance, rats receiving moderate CCI showed
large and permanent deficits; in contrast, no deficits were seen in
rats receiving mild CCI [8].
TBI damages both white and grey matter, but markers of white
matter injury are now thought to better correlate with higher brain
function [14]. TBI readily injures long white matter tracts such as
the corpus callosum, fimbria-fornix, hippocampal commissure and
internal capsule [15]. This study assayed myelin loss in these white
matter regions after moderate CCI.
Clinical or experimental TBI produces a large and rapid
increase in interleukin-1 beta (IL-1) [16,17,18]. Il-1 levels reach a
maximum in the hippocampus 1–2 hours after injury [18].
Perfusion into the brain of the interleukin-1 receptor antagonist,
reduced lesion volume and improved learning of platform location
in the Morris water maze [19]. Conversely, IL-1b infusion
increased lesion volume in the fluid percussion model of TBI
[20]. These observations suggest a key role for IL-1b in the
pathophysiology of TBI.
The present study examined the effects of both drugs and drug
combinations on active place avoidance learning during massed
training as well as during spaced training, consisting of a single 20-
minute trial per day for 15 days. Massed training tests for learning
mediated by short-term task retention plus perceptual segregation;
spaced active avoidance also tests for 24-hour retention [11,12].
This study identified MINO plus NAC as a synergistic drug
combination based on their ability to improve performance on the
active place avoidance task. The effects of MINO plus NAC,
individually and in combination, were also examined on
prevention of myelin loss and IL-1b production.
Results
MINO improved active place avoidance following CCI
Five drugs - MINO, NAC, cyclosporine, simvastatin and
progesterone - were selected because they were previously
reported to limit TBI in rats [1,18,21,22,23,24,25]. Seven groups
were tested: (1) Sham-CCI-saline; (2) CCI-saline; (3) CCI-MINO;
(4) CCI-NAC; (5) CCI-cyclosporine; (6) CCI-simvastatin; (7) CCI-
progesterone. Seven days following surgery, rats were assayed in
the open field and passive place avoidance tasks. No differences
were observed suggesting that all groups had similar innate,
sensory and motor function (Table 1). The following day all groups
were tested on massed active place avoidance (Figure 1). The total
number of entrances in the massed training trials of active place
avoidance showed a significant group effect of drug treatment with
sham-CCI-saline rats having fewer entrances than the CCI-MINO
group (F6,35=50.83; p,0.0001, post-hoc: p’s,0.001) (Figure 1).
All groups showed a significant trial effect demonstrating that
some groups learned while others did not (F5,175=280.22,
p,0.0001). To further analyze whether individual groups
improved across trials, one-way ANOVA showed no significant
improvement in the CCI-cyclosporine, CCI-simvastatin or CCI-
progesterone and CCI-saline groups. Although there were
differences among in task acquisition, all groups were able to
reduce the number of entrances (F4,25=146.43, p,0.01). These
differences were further supported by a significant trial effect
Table 1. Measurements of rat behavior during open field, passive place avoidance and active place avoidance.
Task Parameter
Sham
CCI- Saline CCI-saline CCI- CYCLO CCI-SIM CCI-PROG CCI-MINO CCI-NAC
CCI-MINO
plus NAC
Open Field Total Distance 26.860.98 25.461.5 27.163.7 24.263.5 26.362.7 27.762.2 28.061.7 26.361.7
Passive Place
Avoidance
Shock zone entrances 1360.75 1860.89 1860.77 2260.76 1560.96 1460.49 1660.42 1460.42
Total Distance 7.860.3 7.360.5 6.960.5 7.760.7 7.160.7 6.460.6 6.760.5 7.060.6
Active Place
Avoidance
Speed 5.860.3 5.160.4 5.760.5 4.360.4 6.160.3 5.660.2 5.060.3 5.460.3
Linearity 0.6060.03 0.6460.04 0.7160.04 0.7560.05 0.6660.01 0.6760.03 0.6560.03 0.6260.03
Shocks/Entrance 0.460.2 1.260.02 1.360.1 1.260.1 1.160.04 1.060.04 1.160.04 1.160.04
Time to first entrance 472.5663.4** 46.565.6 39.865.1 42.963.8 45.662.8 146.0633.4* 52.967.3 243624.0**
Rats received either sham- or moderate-CCI. Beginning one hour after surgery the rats received either saline, cyclosporine (CYCLO) simvastatin (SIM), progesterone
(PROG), minocycline (MINO), n-acetyl cysteine (NAC) or MINO plus NAC. Seven days later all groups were tested on the hierarchy of three behavioral tasks. In the open
field test, there was no effect of treatment on total distance traveled (F7,40=0.40, p.0.8). In passive place avoidance, there was no effect of treatment on either average
distance over 4 trials or shock zone entrances (total distance, F7,40=0.67, p.0.6; entrances, F7,40=0.48, p.0.8). In massed active place avoidance testing on the 6
th trial
of the first day, there was no effect of treatment on speed (F7,40=0.44, p.0.8) or linearity (F7,40=0.25, p.0.9)). The number of shocks per entrance in CCI-saline treated
rats was not changed by the drugs individually or in combination (F7,40=0.39, p.0.6). In contrast, there was a significant treatment effect with MINO or MINO plus NAC
significantly improved time to first entrance (F4,35=26.7, p,0.0001; **p,0.001, *p,0.05; post-hoc test).
doi:10.1371/journal.pone.0012490.t001
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differed among groups. No interaction was noted between the
factors of group and trials (F20,125=9.24, p=0.41) indicating that
changes in group and trials were independent. The CCI-
cyclosporine, CCI-simvastatin or CCI-progesterone and CCI-saline
group showed no significant improvement across trials (1- way
ANOVA; CCI-cyclosporine, F5,25=28.6, p=0.33; CCI-simvasta-
tin, F5,25=33.65, p=0.25; CCI-progesterone, F5,25=36.28,
p=0.31; CCI-saline, F5,25=44.61, p=0.28). Only MINO im-
proved active place avoidance learning during massed training (1
way ANOVA, F=54.26, p,0.01) even though all the drugs were
administered at doses that were effective at reducing TBI
[1,18,21,22,23,24,25]. MINO was therefore chosen as one arm of
the combination therapy to treat CCI.
MINO plus NAC synergistically improved active place
avoidance following CCI
MINO was first combined with cyclosporine. Within 4 days
after injury, all rats died after receiving MINO, cyclosporine
(n=4). This contrasts with the 100% viability of rats that received
MINO or cyclosporine as single drugs. NAC was selected as the
next drug to be tested given its extensive safety record at the dose
tested [26]. Rats were divided into five groups to test whether
NAC had an effect on the ability of MINO to improve active place
avoidance; (1) Sham-CCI-saline; (2) CCI-saline; (3) CCI-MINO;
(4) CCI-NAC; (5) CCI-MINO plus NAC. At one week following
injury no difference in open field and passive avoidance was
observed, suggesting similar abilities to initiate and inhibit
exploration, as well as sense and avoid shock (Table 1). All groups
then received two days of 6 trials of active avoidance (Figure 2A).
Group differences were observed in both the representative paths
during trial 6 and the learning curves during massed active place
avoidance training (Figures 2B and C). The sham-injured group
receiving saline learned the task rapidly, entering the shock zone
only once on trial 6. The injured groups receiving MINO or
MINO plus NAC were partially impaired as their learning curves
were initially flat; improvement became evident after trial 3, with a
less steep learning curve than the sham-CCI-saline group. By trial
6, the CCI-MINO or CCI-MINO plus NAC groups had fewer
than 8 shock zone entrances. The CCI-saline or CCI-NAC groups
were more profoundly impaired. Their performance was worse
than the other groups on trial 1, suggesting there was limited
within-trial learning. By trial 6, they entered the shock zone more
than 14 times, which was no better than the other groups on their
first trial. The CCI-saline or CCI-NAC groups tended not to avoid
the shock zone, instead they rapidly left the zone only after
receiving a shock, suggesting that they lowered the number of
entrances by rapidly running after being shocked. A comparison of
the representative tracks in figure 2B provides evidence of this
behavior. The sham-CCI track showed smooth trajectories as the
rat actively avoided the shock zone. In contrast, the concentric
circular paths of the track of CCI-saline group illustrates that the
rat remained motionless as it was passively carried into the shock
zone by the clockwise arena rotation. Therefore, the locations of
the rat when it was shocked were largely located in the counter-
clockwise half of the shock zone. In contrast, the MINO plus
NAC-treated group, like the sham-CCI-saline group, only became
active as they approached the shock zone. The tracks also show
that MINO plus NAC-treated animals were less successful than
the sham-CCI animals to avoid being shocked. Although there
were group differences, all groups were able to reduce the number
of entrances (F4,25=146.43, p,0.01). This confirmed group
differences in task acquisition. These differences were further
supported by a significant trial effect (F5,125=285.31, p,0.01), yet
no interaction was noted between the factors of group and trials
(F20,125=9.24, p=0.41). Post-hoc tests further confirmed that the
Sham-CCI-saline, CCI-MINO plus NAC, and CCI-MINO had
reduced shock zone entrances as compared to the CCI-saline, and
CCI-NAC groups which did not differ.
An important, surprising feature of learning curves was on the
1st trial of the second day (trial 7) of active place avoidance testing
(Figure 2C). Comparing avoidance on trial 7 confirmed a
significant group effect (F1,14=6.53; *p=0.02). Even though the
CCI-MINO and CCI-MINO plus NAC groups had similar
avoidance throughout day 1, the CCI-MINO group had more
entrances on trial 7. This observation suggested that the NAC
synergistically improved 24-hour retention since the MINO plus
NAC group performed better than MINO group despite no effect
of NAC (post-hoc, p,0.01).
To confirm and further elucidate a potential synergy between
MINO plus NAC, a second study was performed using spaced
active place avoidance training because improved avoidance in
this protocol relies on both 24-hour retention across sessions as
well as within-session processes (Figure 3A). An additional five
groups of rats were evaluated (Sham CCI-saline; CCI-saline; CCI-
MINO; CCI-NAC; and CCI-MINO plus NAC). All groups
performed similarly in the open field and passive avoidance tasks
(table 1). In the spaced version of active place avoidance, group
differences were apparent in the learning curves (F4,25=34.68;
p,0.01; Figures 3B and C). The effect of trial was also significant
indicating that some groups learned to reduce the number of
entrances across trials (F14,350=72.86; p,0.01). There was no
interaction between the factors of group and trial (F56,350=3.83;
p=0.26). Time to first entrance showed a similar pattern
(Figure 3C). The sham CCI-saline group steadily increased in
the ability to delay entering the shock zone, which increased to
over 18 minutes. The CCI-MINO plus NAC group showed a less
steep increase that plateaued at more than 8 minutes. This
indicated a substantial improvement of avoidance learning and
long-term memory. Rats in the remaining groups did not increase
the time to first entrance beyond one minute, confirming a severe
impairment of long-term memory seen in the earlier, massed
protocol of active place avoidance (Figure 2C).
By the 7
th trial of spaced active place avoidance training, the
sham-CCI-saline group reached asymptote on the parameters of
Figure 1. MINO provided a modest improvement of active
place avoidance following moderate CCI. The total number of
entrances into the shock zone was assayed in the 6 trials of active place
avoidance training.
doi:10.1371/journal.pone.0012490.g001
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The other groups reached asymptote only in the number of
entrances. Therefore, statistical comparisons were performed on
the 7
th trial of all groups. There was a significant effect of group (1-
way ANOVA, F4,25=37.26, p,0.01). The sham-CCI-saline rats
optimally avoided the shock zone and post-hoc comparisons
confirmed that the CCI-MINO plus NAC group had significantly
fewer entrances than the CCI-MINO group. The CCI-MINO
group, however, performed better than the groups receiving NAC
or saline. Thus total entrances, a parameter that is affected by both
within-session learning and memory between sessions, showed a
synergistic interaction between MINO plus NAC since NAC
enhanced MINO action yet was ineffective as a single drug.
The time to 1
st entrance, the parameter that most directly
measures 24-hour memory also showed drug synergy. The effect
of group was significant (F4,25=206.15, p,0.01) as was the effect
of trial (F14,50=62.42, p,0.01), indicating learning in at least
some of the groups. The interaction between group and trial was
not significant (F56,350=30.72, p=0.33). At the end of training, on
day 15, there was a significant effect of groups (Figure 3C). Post-
hoc tests confirmed that the CCI-MINO plus NAC group had an
elevated time to 1
st entrance as compared to the CCI-saline, CCI-
NAC, and CCI-MINO groups, which did not differ. The MINO
plus NAC group did not increase time to 1
st entrance as well as the
sham CCI-saline group. These data provide strong evidence for
drug synergy since MINO plus NAC combination was highly
effective while the drugs were ineffective as monotherapy.
Prevention of myelin loss by MINO plus NAC following
TBI
After the completion of spaced active place avoidance training,
rats were sacrificed, coronal brain sections were prepared and the
loss of cortical tissue at the impact site was assayed. There was no
Figure 3. MINO plus NAC synergistically improved active place avoidance during spaced training that requires 24-hour memory.
Panel A, Experimental Design. Rats received moderate CCI or sham-injury. Saline or drug treatments were administered 1 hour, 1 day and 2 days
after injury. Beginning 8 days after injury, rats received spaced training of active place avoidance consisting of a 20-minute trial each day for 15 days.
Panel B, The number of entrances into the shock zone measured overall avoidance learning. Panel C, Time to 1st entrance into the shock zone
measured learning that depended on 24-hour retention. These data suggest that long-term memory was improved by MINO plus NAC but not MINO.
MINO plus NAC acted synergistically since the improvement in time to enter the shock zone occurred only with co-administration of both drugs.
doi:10.1371/journal.pone.0012490.g003
Figure 2. MINO plus NAC synergistically improved active place avoidance after massed training. Panel A, Rats received either CCI or
sham-CCI. One hour, one or days later the sham-injured the CCI-injured rats were divided into 4 groups; one group received saline treatment. The
remaining CCI-injured rats received either MINO or NAC alone, or the combination of MINO plus NAC. Saline or drug treatments were administered
1 hour, 1 day and 2 days after injury. Rats received active place avoidance training 8 and 9 days after injury. On the 8th and 9th day following CCI, the
number of shock zone entrances was measured. Panel B, Representative tracks of rats in the sham-CCI-saline, CCI-saline or CCI-MINO plus NAC
groups on the 6
th trial on the first day of active avoidance training. Red lines indicate the boundaries of the shock zone and the red circles indicate
the location were a rat received a shock. Panel C, Summary of the number of shock zone entrances over the two days of active place avoidance.
doi:10.1371/journal.pone.0012490.g002
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individually or in combination, has little effect on lesion volume
(expressed as the percent difference from contralateral hemi-
sphere) CCI-saline, 100.064.9%; CCI-MINO, 92.267.8%; CCI-
NAC, 86.066.1%; CCI-MINO plus NAC, 87.466.4%;
F3,36=1.1, p.0.4).
Myelin loss was assayed in adjacent coronal sections using the
myelin-specific stain Luxol fast blue. Six white matter structures
were examined- corpus callosum, dorsal hippocampal commis-
sure, fimbria, internal capsule, fornix and mamallothalamic tract
(Figure 4A). Moderate CCI reduced myelin content in many, but
not all white matter regions and there were significant effects of
group in all regions except the mamallothalamic tract suggesting
impact of the drug treatments (corpus callosum, F4,10=8.85,
p,0.01; hippocampal commissure, F4,10=25.75, p,0.0001;
fimbria, F4,10=11.44, p,0.01; internal capsule, F4,10=13.15,
p,0.01; fornix, F4,10=5.76, p,0.01; mamallothalamic tract,
F4,10=1.20, p.0.3) (Figure 4B, C). NAC treatment limited
myelin loss in the corpus callosum, but not in the other white
matter tracts (post-hoc, p,0.05). MINO or MINO plus NAC
treatment were similarly effective in preventing myelin loss (post-
hoc, p=0.23) (Figure 4C). These data suggest that MINO plus
NAC prevented myelin loss after moderate CCI. Unlike the
synergistic improvement in behavior, MINO plus NAC showed an
indifferent drug effect since MINO plus NAC was no more
effective than MINO alone.
MINO plus NAC synergistically inhibit IL-1b production
when dosed before moderate CCI
Hippocampal IL-1b rapidly increases following TBI [17]. IL-1b
levels were lowered by treatment with either MINO or NAC.
Figure 4. MINO plus NAC prevented myelin loss. Panel A, Schematic of the regions of interest (ROIs) from a coronal section located 23.36 mm
from Bregma [40]. The ROIs were: corpus callosum (A), dorsal hippocampal commissure (B), stratum radiatum (C), fimbria (D), internal capsule (E),
fornix (F), mammilothalamic tract (G). Panel B, Representative images of corpus callosum and dorsal hippocampal commissure stained with luxol fast
blue. B1, Sham-CCI-saline; B2 CCI-saline; B3, CCI-MINO plus NAC. The scale bar corresponds to 100mm.
doi:10.1371/journal.pone.0012490.g004
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combination lowered IL-1b levels, five groups (Sham-CCI-saline;
CCI-saline; CCI-MINO; CCI-NAC; and CCI-MINO plus NAC)
were examined. Rats were treated with saline or drugs three hours
prior to sham-CCI or CCI, and hippocampal IL-1b levels were
assayed one hour later (Figure 5). There was a significant effect of
treatment (F4,15=14.84, p,0.01) with an increase in hippocampal
IL-1b levels following moderate CCI that was significantly blocked
by MINO plus NAC (post-hoc, p,0.001). Surprisingly, when
dosed 3 hours prior to injury, neither MINO nor NAC as single
drugs blocked the IL-1b increase despite their efficacy as a
combination (post-hoc, p=0.6). These data suggest that MINO
plus NAC act synergistically to lower IL-1b levels when dosed
before moderate CCI.
The dosing of drugs prior to injury provided insight into drug
action but did not address whether the post-injury dosing of
MINO plus NAC also regulated IL-1b levels after moderate CCI.
To test whether these drugs acted similarly when dosed after
injury, rats received either saline or MINO plus NAC one hour
after moderate CCI. Four hours after injury, the rats were
sacrificed and hippocampal IL-1b levels were measured. Western
blot analysis showed no significant change in IL-1b levels in the
hippocamppi of CCI-treated rats receiving post-injury treatments
of either saline or MINO plus NAC (saline, 1.061.9 (n=4);
MINO plus NAC, 1.4560.42 (n=4); t6=0.24; p.0.05). These
data suggest that MINO plus NAC did not affect hippocampal IL-
1b levels when dosed one hour after injury.
Discussion
This study identified three actions of the drug combination of
MINO plus NAC following moderate CCI: (1) MINO plus NAC
synergistically prevented cognitive deficits by improving learning
as well as memory spanning at least 24-hours in the active place
avoidance task (Figures 2 and 3), (2) myelin loss was prevented by
either MINO alone or MINO plus NAC (Figure 4), and (3) MINO
plus NAC synergistically prevented IL-1b formation when dosed
before, but not after injury (Figure 5).
MINO plus NAC synergistically improved both task acquisition
and reduced memory loss when treatment began one hour
following moderate CCI (Figures 2 and 3). Moderate CCI was
previously shown to produce large, long-lasting deficits in active
place avoidance during massed training that prevented further
testing if there was a further impairment of short- or long-term task
retention [8]. MINO- and MINO plus NAC-treated animals
acquired active place avoidance during massed training, which
allowed us to examine if the drugs also improved short- and long-
term task retention (Figure 2 and 3). MINO-treated animals had
short-term retention of the massed active avoidance task (Figure 2).
During the spaced protocol of active place avoidance, despite a
modest decrease in the number of entrances, the MINO plus
NAC-treated rats showed only a slight improvement of time to first
entrance into the shock zone suggesting no long-term retention of
shock zone location (Figure 3). Thus, the modest improvement in
number of entrances is unlikely to be due to memory for the shock
zone itself. Rather, it is likely due to non-specific, non-spatial
learning or adoption of a sub-optimal behavioral strategy such as
remaining motionless until receiving a shock. The MINO-treated
animals were also impaired in long-term retention as seen in their
performance in the first trial of the second day of active place
avoidance (Figures 2). NAC enhanced MINO action, but had little
effect on active place avoidance as a single drug in either massed
or spaced training. These data strongly suggest a synergistic effect
between MINO plus NAC as seen in the first trial of the second
day of active avoidance during massed training as well as
throughout spaced training (Figures 2 and 3). Synergy often
predicts the most potent drug combinations [7].
MINO plus NAC had little effect on the loss of cortical tissue at
the impact site 14 days following moderate CCI. A widespread loss
of myelin distal to the impact site was also observed (Figure 4).
This widespread myelin loss agrees with previous studies showing
widespread axonal damage distal to the impact site following CCI
in both rats and mice [30,31]. Myelin loss was observed in midline
white matter structures such as corpus callosum and dorsal
hippocampal commissure as well as more lateral white matter
structures such as fimbria and internal capsule. The demonstration
Figure 5. MINO or MINO plus NAC prevented IL-1b formation when administered before moderate CCI. Rats were dosed with saline,
MINO, NAC or both drugs 3 hours prior to sham- or moderate CCI. The rats were sacrificed one hour after surgery; and IL-1b and tubulin levels were
assayed from protein extracts prepared from hippocampus. Panel A, Representative Il-1b and tubulin immunoblot analysis, Panel B, Summary of
immunoblot analysis.
doi:10.1371/journal.pone.0012490.g005
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MINO alone suggested that NAC acted indifferently to MINO.
Improved white matter function is the likely result of better
preservation of myelinated fibers. Injured animals had similar
performance in passive place avoidance whether they received
saline- or drug-treatment (Table 1). In contrast, MINO-treated
animals partially acquired active place avoidance during massed
training (Figure 2). Rats perceive both distal and proximal cues in
active place avoidance but only the distal cues provide
information needed to avoid the shock zone [11]. Thus, avoiding
the shock zone likely requires the concerted action of multiple
brain regions [13,32,33]. Both hippocampi as well as hippocam-
pal LTP are necessary for active place avoidance learning and
memory retention [12,13,34]. The hippocampal commissure
provides monosynaptic connections between the two hippo-
camppi; myelin loss in the hippocampal commissure was
prevented by MINO plus NAC [35]. Myelin loss in the
hippocampal commissure in moderately injured animals may
result in a conduction block that can impair hippocampal
function (Figure 4) [35]. Improved behavior in rats receiving
MINO or MINO plus NAC may result from partial prevention of
myelin loss. A similar prevention of myelin loss occurred with
MINO or MINO plus NAC. These data suggest that the
prevention of myelin loss does not fully explain why MINO plus
NAC is more potent than MINO alone. MINO plus NAC
treatment improved active place avoidance in both the massed
and spaced versions of training active avoidance. MINO plus
NAC-treated rats improved long-term memory despite a similar
prevention of myelin loss a rats receiving MINO alone.
Either MINO or NAC inhibit IL-1b formation when dosed or
within 30 minutes after experimental TBI [18,27]. A potent,
synergistic inhibition of IL-1b formation was seen when MINO
plus NAC was dosed 3 hours before injury (Figure 5). No change
in IL-1b formation, however, occurred when the drugs were dosed
one hour post-injury. At identical doses used in this study, IL-1b
formation was inhibited when MINO was dosed 30 minutes or
NAC 15 minutes post-injury [18,27]. These data suggest that IL-
1b formation that occurs within 30 minutes of experimental TBI
can be blocked by MINO or NAC. In contrast, later IL-1b
formation remains unchanged after MINO or NAC treatment.
These data also suggest that the cognitive and memory
improvements produced by MINO plus NAC dosed 1 hour after
injury occurs independently of IL-1b formation.
The actual pharmacological targets of MINO are not clear, but
the downstream effects of MINO include suppression of
inflammation and apoptosis [36,37]. More is known about the
action of NAC. NAC directly elevates glutathione in the brain that
scavenges cytoplasmic reactive oxygen species. The anti-oxidant
effect of NAC results in widespread changes in both signaling
molecules and transcription factors [26]. NAC may also increase
extrasynaptic glutamate by increasing the activity of glutamate-
cystine transporters [38]. Thus, there are large and complex
potential interactions of MINO and NAC. These interactions
potentially impact on many aspects of brain function that are more
likely to be revealed by assessing complex brain functions using
assays such as active place avoidance behavior rather than with
tests with more focused outcomes such as inhibition of IL-1
formation (Figures 3 and 5).
MINO had more efficacy than NAC in limiting injury following
moderate CCI. MINO improved performance on massed active
place avoidance (Figures 1 and 2) and prevented myelin loss
(Figure 5). NAC showed little efficacy as a single drug. NAC,
however, potently reduces brain redox, suggesting that MINO
may be more potent in a more reducing environment [26].
MINO plus NAC are in multiple clinical trials as individual
drugs against a variety of neurodegenerative diseases. Although
none of these trials have led to the clinical use of these drugs to
treat neurodegeneration, the sheer number of ongoing trials attests
to both the efficacy and safety of MINO plus NAC as individual
drugs. The finding that MINO plus NAC can act synergistically
suggests the combination may show enhanced efficacy not only
against TBI, but other neurological diseases as well.
Materials and Methods
Ethics statement
All animal work must have been conducted according to
relevant national and international guidelines. In addition, all
procedures were done according to protocol 03-054-10 that has
been approved by the SUNY-Downstate Institutional Animal
Care and Use Committee (Assurance number A3260-01).
Production and treatment of CCI
Moderate CCI was produced as described by Abdel Baki et al.
[8]. Briefly, Sprague-Dawley rats (250–300g, Charles River,
Wilmington, MA) were anesthetized using isoflurane (3–5%) in
oxygen (0.8 L/min) and a unilateral craniotomy (6.0 mm) was
performed midway between lambda and bregma. A 5.0 mm
impactor tip compressed the cortex to a depth of 2.5 mm at 4 m/
sec (myNeurolab.com, St. Louis, MO). Rats received three
injections of single drugs or drug combinations one hour and
one and two days after surgery. The doses of minocycline (45 mg/
kg, [18], N-acetylcysteine (150 mg/kg, [21], cyclosporine A,
(20mg/kg, [23], progesterone (32 mg/kg, [24], and simvastatin
(1mg/kg, [25] were chosen from previous studies that improved an
assortment of brain injury parameters. All drugs were injected
intraperitoneally, except for simvastatin that was administered by
oral gavage.
Behavioral Analysis
Rats were tested on a hierarchy of computer-controlled
behavioral tasks using a commercial hardware and software
system (ITS, Bio-Signal Group, Brooklyn, NY) as described by
Abdel Baki, et al., 2009 [8]. All tasks were done on an 82-cm
diameter metal arena with a 40-cm high transparent wall that
allowed the rat to view prominent visual cues in the room. Motor
function returns to preinjury levels by 7 days thus ensuring that
altered motor function does not alter performance on the
hierarchy of behavioral tasks (Table 1). Beginning seven days
after surgery, rats were tested on three behavioral tasks. During
each task, the rat’s location was identified each 33 ms by the
video-tracking system, which delivered a mild electrical foot shock
according to the parameters of the software algorithm that
controlled the experiment (Tracker, Bio-Signal Group, Brooklyn,
NY). The data were stored for off-line computation of a variety of
behavioral parameters using TrackAnalysis software (Bio-Signal
Group, Brooklyn, NY).
The first task of the hierarchy was an open-field test. The arena
was stationary and no shocks were administered. The distance
traveled assayed habituation to the arena, a measure of innate
exploratory behavior. Immediately after open-field testing, rats
received the second task of the hierarchy. For this passive place
avoidance test, a computer-controlled 60u shock zone was added
to the stationary arena. Rats received four 10-minute tests of
passive place avoidance with a 10-minute intertrial interval. The
total number of shock zone entrances measured the ability to avoid
the shock zone and the distance traveled assayed an aversively
conditioned ability to inhibit movement. The following day, rats
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massed or the spaced training protocol. During active place
avoidance the arena rotated at 1 rpm. The arena also has a
stationary 60u shock zone that remained fixed across trials. During
massed training, rats received six 10-minute trials for either one or
two days with a 10-minute intertrial interval. The number of shock
zone entrances assayed learning that relied on hippocampus-
dependent short-term, but not long-term memory [12]. In the case
of two days of active place avoidance, the first trial of the second
day (the 7
th trial of 12 total trials) assayed 24-hour memory
retention of the shock zone location. During spaced active placed
avoidance training, rats received one 20-minute trial each day for
15 days. Time elapsed before the first entrance into the shock zone
assayed 24-hour task retention during learning and the number of
entrances assessed task acquisition that is influenced by a variety of
factors including motivation to avoid shock, sensitivity to shock,
anxiety, stress, short-term memory, perceptual salience of cues,
ability to navigate, ability to inhibit locomotion, ability to initiate
escape behaviors, choice of behavioral strategy, ability to select
appropriate behaviors, cognitive control, attention, in addition to
24-hr retention [39]. Average speed was determined by computing
speed every 2 seconds. Linearity assessed path trajectory and is
defined as the average of the following ratio:
linearity~dist(linear)=dist(integrated)
Dist(integrated) is the sum of the distances moved each 33 ms in the
2-second interval, and dist(linear) is the linear distance between the
locations at the start and end of the 2-second interval. Behavioral
parameters were analyzed using 2-way repeated-measures ANOVA
by comparing treatment of groups across trials. A primary goal was
to measure asymptotic behavior differences between groups,
therefore, 1-way ANOVA planned comparisons evaluated group
differences on a particular training day or on performance across an
entire training protocol. When appropriate, Newman-Keuls post-
hoc tests compared group differences.
Histological Analysis
Fourteen days after sham- or moderate-CCI, urethane (1.2 g/
kg, i.p.) followed by transcardial infusion with paraformaldehyde
(4% (w/v)), coronal brain sections were prepared as described in
Abdel Baki, et al., 2009 [8]. Coronal sections were stained using
Luxol fast blue according to the manufacturer’s instructions
(American Mastertech, Lodi, CA). Digital images were prepared
and the amount of Luxol Fast Blue staining was assayed using
Image J software in regions of interests (ROIs) within the corpus
callosum, dorsal hippocampal commissure, fimbria, internal
capsule, fornix, and mamallothalamic tract in coronal sections
located 23.10–3.45 mm from Bregma [40]. To determine the
amount of Luxol fast blue staining that was due to myelin staining,
staining intensity in the ROIs was subtracted from staining
intensity values from the stratum radiatum of the hippocampus
that contained the umyelinated Schaffer collateral. A recent study
showed a positive correlation between luxol fast blue staining and
the parameters of fractional anisotropy and radial diffusivity in rats
following experimental TBI [41].
Lesion volume in the ipsilateral cortex was determined by the
method of Raghupathi and Huh, 2007 [42]. Lesion volume
(expressed as the percentage difference from the contralateral
cortex) was calculated from a series of adjacent coronal sections
using the formula:
S(f½CAi-IAi)z(CAiz1-IAiz1) =2g dit oi z1)=
S(f½CAizCAiz1 =2g dit oi z1)   100
where dit oi +1 is the distance between sections i and i+1; IAi and
IAi+1 are the areas of lesioned cortex; and CAi and CAi+1 are the
corresponding areas of unlesioned cortex. Lesion volume in all
groups was normalized to values from CCI-saline rats.
Assay of IL-1b production
To examine the effect of dosing drugs before injury, rats were
treated with saline MINO, NAC or MINO plus NAC three hours
before sham-CCI or moderate CCI. One hour after surgery, rats
were anesthetized with halothane and decaptitated. The hippo-
campi were rapidly removed and frozen in liquid nitrogen. To
examine an effect of dosing drugs after injury, rats received sham-
or moderate CCI and were treated with saline or drugs one hour
after injury. Three hours after saline or drug treatment,
hippocamppi were removed in an identical manner as the
preinjury study.
Protein was extracted by grinding the tissue while rapidly
thawing in Tris-HCl, (120mM, pH 6.8) and SDS (4%, w/v) at
100uC for 10 minutes followed by centrifugation at 13,000g for
5 minutes. Protein extract (30ug) was analyzed by immunoblot
using an antibody against b-tubulin (1/1000 dilution; ab7792,
Abcam, Inc., Cambridge, MA) and against IL-1b (1/1000
dilution, #2021, Cell Signaling, Inc., Danvers, MA). Group
comparisons were made by ANOVA followed by Newman-Keuls
post-hoc tests. Significance was p,0.05. All values are reported as
the mean 6 SEM.
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